Core Viewpoint - MBX Biosciences, Inc. has filed a registration statement for a proposed public offering of 10,000,000 shares of common stock, with an additional option for underwriters to purchase up to 1,500,000 shares [1][2][3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders, utilizing its proprietary PEP™ platform [6] Offering Details - The public offering price has not yet been determined, and the offering is subject to market conditions [1] - J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering, with Citizens Capital Markets and Oppenheimer & Co. as co-lead managers [2] - The registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [3] Prospectus Information - The proposed offering will be made only by means of a prospectus, which can be obtained from the respective financial institutions involved in the offering [4]
MBX Biosciences Announces Proposed Public Offering